Leukemia Therapeutics Market: Robust Growth Expected with Innovative CAR-T Treatments
23 janv. 2024 15h23 HE
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
30 oct. 2023 09h15 HE
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Global Leukemia Therapeutics Market Report 2023: Rising Prevalence of Leukemia is Driving Growth
08 mai 2023 05h33 HE
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Leukemia Therapeutics Global Market Report 2023: Rises in Product Approvals and Increasing Diagnosis Awareness Drives Growth
02 mai 2023 07h33 HE
|
Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
12 avr. 2022 07h00 HE
|
Cyclacel
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...
Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey
05 août 2021 07h28 HE
|
Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The...
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
09 déc. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
06 nov. 2019 09h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
13 août 2019 16h05 HE
|
Cyclacel
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or...
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
22 juil. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...